Skip to content
  • Home
  • About us
  • Clinical trials
  • Blog
  • Contact us
  • Home
  • About us
  • Clinical trials
  • Blog
  • Contact us
Get started
icon
icon

icon
icon
icon Medical trials / View details
cancle-icon

Chest Lymph Node Sampling in Patients With Advanced Lung Cancer to be Treated With Curative-intent Radiation Treatment

Contact information

icon Inderdeep Dhaliwal, MD

icon London Health Sciences Centre - London Regional Cancer Program

icon London, Ontario, Canada, N6A 5W9

Basic information

icon

icon 18-30, 31-40, 41-50, 51-60, 61-70, Over 70 Age

icon 29 Enrollment

icon
Lung Cancer
Trial Details
Brief Summary

This study will investigate the role of sampling suspicious chest lymph nodes with a procedure called endobronchial ultrasound-guided transbronchial fine needle aspiration (EBUS-TFNA) or transesophageal ultrasound-guided fine needle aspiration (EUS-FNA) in patients planned to receive radical dose radiation. This study will use Stereotactic Ablative Radiotherapy (SABR) for treatment methods. SABR is a newer radiation treatment that delivers high-dose, precise radiation to small tumors and can be delivered more accurately than with older radiation treatment methods. It is considered a standard treatment for small lung cancers, and select cancers that have spread to the brain. The purpose of this study is to compare if the lymph node sampling procedure is valuable for determining the extend of nodal disease in metastatic Non-Small Cell Lung Cancer (NSCLC) compared to imaging alone.

Official Title

Endoscopic Nodal Staging in Oligometastatic Non-small Cell Lung Cancer (NSCLC) Being Treated With Stereotactic Ablative Radiotherapy (ENDO-SABR)

Selection Criteria
Eligibility Inclusion Criteria
    - Patients with oligometastatic non-small cell lung cancer (NSCLC), including a primary lung tumour (± hilar/mediastinal adenopathy) with up to 5 synchronous metastases
    - Radical treatment intent to all sites is recommended at multi-disciplinary tumour board or by discussion by medical oncologist and radiation oncologist and/or surgeon.
    - Age 18 years or older
    - Good performance status (Eastern Cooperative Oncology Group [ECOG 0-1) with life-expectancy of at least 6 months as determined by enrolling physician
    - Patient has undergone staging investigations less than 3 months prior to registration.

    - Positron Emission Tomography (PET) / Computed Tomography (CT) and Magnetic Resonance Imaging (MRI) brain (CT brain with contrast if contraindication to MRI) OR
    CT chest/abdomen, radionucleotide bone scan and MRI of brain (CT brain with contrast if contraindication to MRI)
    - Pathologic confirmation of NSCLC
Eligibility Exclusion Criteria
    - Contraindication to Endobronchial Ultrasound (EBUS) / ---- Endoscopic Ultrasound (EUS)
    - Unable to provide consent for EBUS/EUS
    - Contraindication to chest radiotherapy
    - Pregnant or lactating women

Join us! Be part of the smart work revolution.

Explore articles with tips and insights to know your about clinical matching

Contact us
Navigation
  • Home
  • About us
  • Clinical trials
  • Blog
  • Home
  • About us
  • Clinical trials
  • Blog
Address

L1N6Y1 / 26

Winston Crescent

Whitby, ON

Canada

Legal
  • Terms of use
  • Privacy Policy
  • Contact us
  • Terms of use
  • Privacy Policy
  • Contact us
Contact
+1 587-664-4986 info@horizonnt.ca
Get in touch
Horizon trial
  • Home
  • About us
  • Clinical trials
  • Blog
  • Contact us
  • Home
  • About us
  • Clinical trials
  • Blog
  • Contact us
Get started